SAN Sanofi

By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of Dupixent to treat children with severe atopic dermatitis.

The companies said the recommendation covers the treatment of patients ages six to 11 years with severe atopic dermatitis who are candidates for systemic therapy.

The European Commission, which generally follows the CHMP's advice, is expected to announce a final decision in the coming months, the companies said.

Dupixent is already approved for the treatment of uncontrolled moderate-to-severe atopic dermatitis for people 12 years of age and older in the EU and six years of age and older in the U.S.

Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 16, 2020 08:36 ET (12:36 GMT)

Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024

Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024